Showing 101 - 120 results of 175 for search '"University of Utah"', query time: 0.07s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120

    Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation by Vera V, Sheybani A, Panarelli JF, Grover DS, Lee J, Craven ER, Samuelson TW, Ahmed IIK

    Published 2025-01-01
    “…Vanessa Vera,1 Arsham Sheybani,2 Joseph F Panarelli,3 Davinder S Grover,4 James Lee,5 Earl Randy Craven,2 Thomas W Samuelson,6 Iqbal Ike K Ahmed7 1Allergan, an AbbVie company, Irvine, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3Department of Ophthalmology, New York University Langone Health, New York, NY, USA; 4Glaucoma Associates of Texas, Dallas, TX, USA; 5Colorado Eye Institute, Colorado Springs, CO, USA; 6Minnesota Eye Consultants, University of Minnesota, Minneapolis, MN, USA; 7John Moran Eye Center, University of Utah, Salt Lake City, UT, USACorrespondence: James Lee, Colorado Eye Institute, Colorado Springs, CO, 80924, USA, Email jlee@eyescolorado.comAbstract: The XEN® 45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. …”
    Get full text
    Article